Kinase inhibitors

A compound of formula (II)

• or a therapeutically acceptable salt thereof, wherein
• L1 is selected from the group consisting of a bond, —O—, —N(R5)—, alkenyl, alkynyl, —N(R5)C(O)—, and —C(O)N(R5)—;
• L2 is selected from the group consisting of a bond, —O—, —N(R5)—, —N(R5)C(O)—, and —C(O)N(R5)—;
• L3 is selected from the group consisting of a bond, alkylidene, and alkylene, wherein the alkylidene and the alkylene are optionally substituted with one or two substituents independently selected from the group consisting of amino, cyano, and hydroxy, with the proviso that if L2 is a bond, —O—, or —S— then L3 is not a bond;
• R1 is selected from the group consisting of monocyclic or bicyclic aryl, heteroaryl, and heterocycle;
• R2 and R4 are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl;
• wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl;
• or
• R2 and L1, together with the carbon atoms to which they are attached, form a ring selected from the group consisting of dihydropyrrolyl, pyrazolyl, and phenyl;
• or
• R4 and L2, together with the carbon atoms to which they are attached, form a ring selected from the group consisting of dihydropyrrolyl, phenyl, pyridinyl, and pyrrolyl;
• wherein the ring can be optionally substituted with oxo;
• provided that when L3 is alkylidene, R4 and L2, together with the carbon atoms to which they are attached, form a ring selected from the group consisting of dihydropyrrolyl, phenyl, pyridinyl, and pyrrolyl;
• wherein the ring can be optionally substituted with oxo;
• R3 is absent or selected from the group consisting of hydrogen, monocyclic or bicyclic aryl, arylalkoxy, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle;
• R6 are independently selected from the group consisting of hydrogen, monocyclic or bicyclic aryl, arylalkoxy, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle;
• provided that when L1 and L2 are bonds, at least one of R3 and R6 is other than hydrogen;
• R5 is selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, arylcarbonyl, arylsulfonyl, and heteroarylsulfonyl;
• and
• X is N.

A compound of formula (III)

• or a therapeutically acceptable salt thereof, wherein
• L1 is selected from the group consisting of a bond, —O—, —N(R5)—, alkenyl, alkynyl, and —N(R5)C(O)—;
• L2 is selected from the group consisting of a bond, —O—, —N(R5)—, —N(R5)C(O)—, and —C(O)N(R5)—;
• L3 is alkylene, wherein the alkylene is substituted with one or two substituents independently selected from the group consisting of amino and hydroxy;
• R1 is selected from the group consisting of monocyclic or bicyclic aryl, heteroaryl, and heterocycle;
• R2 and R4 are independently selected from the group consisting of hydrogen and halo;
• R3 and R6 are independently selected from the group consisting of hydrogen, monocyclic or bicyclic aryl, arylalkoxy, and heteroaryl;
• provided that when L1 and L2 are bonds, at least one of R3 and R6 is other than hydrogen;
• and
• R5 is selected from the group consisting of hydrogen and alkyl.